Imugene’s Azer-cel CAR T Therapy Shows Promising Results in Phase 1b Trial

Imugene ( (AU:IMU) ) has issued an update.

Imugene Limited has announced promising results from its Phase 1b clinical trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy for relapsed diffuse large B-cell lymphoma (DLBCL). The trial has achieved an 81% overall response rate, with 7 complete responses and 6 partial responses among patients who have previously failed multiple lines of therapy. This development highlights the potential of azer-cel in addressing high unmet needs in the treatment of aggressive blood cancers and expands its application to other lymphoma types. The trial is actively enrolling patients in the U.S. and Australia, with additional updates expected in the coming months.

The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited is a clinical-stage immuno-oncology company based in Sydney, Australia. The company focuses on developing innovative therapies for cancer treatment, particularly in the field of CAR T-cell therapies, which are designed to enhance the body’s immune response against cancer cells.

Average Trading Volume: 1,885,216

Technical Sentiment Signal: Sell

Current Market Cap: A$88.75M

See more insights into IMU stock on TipRanks’ Stock Analysis page.